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process in hepatic venous outflow tract obstruction
depends upon degree, site and length of obstruction,
which may influence deterioration despite initial liver
specific good scores.7
The editorial quoted that a report from Mumbai indi-
cates that anticoagulation alone can achieve a complete
clinical and laboratory response in 61% of patients fol-
lowed up for a median of 21 months8. However, our
interpretation of the study differs. Only 7/43 (16%) with
anticoagulation had documented recanalization on imag-
ing; whereas 9/11 (81.2%) who underwent radiological
intervention had restoration of the outflow tract.
The success of the angiographic intervention was
objectively documented by restoration of blood flow
across the narrowed segment with its phasic respiratory
variation. We agree that documentation of the disappear-
ance of the pressure gradient across the obstructed seg-
ment would have objectivized the response more
robustly. But our follow-up and associated clinical
response albeit subjective was additional inputs for
response.
As TIPSS results in the portal venous inflow bypassing
the liver, it is not physiological in comparison to angio-
plasty. Long-term follow-up comparisons of hepatic
venous outflow tract obstruction patients undergoing
angioplasty/stenting and TIPSS were needed to establish
whether a physiological approach should be first line of
therapy in such patients and TIPSS should be offered
with failure of such intervention. We also devised a sim-
ple prognostic score (AIIMS-HVOTO Score) which can
identify patients for liver transplant in hepatic venous
outflow tract obstruction patients.
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Assessing the burden of liver cirrhosis remains pertinent
from a public health standpoint, as end stage liver dis-
ease is among the top 10 leading causes of death
worldwide.1–3 Beyond attributable cause of death, liver
cirrhosis is a chronic condition that can necessitate sub-
stantial medical care. As a result, cirrhosis accounts for
significant health care costs with estimates upwards of
$2.5 billion per year in the USA alone.4 Although there
have been many studies on the incidence, prevalence and
natural history of liver cirrhosis, studies generated from
the Swedish health care system offer specific advantages
due to the nature of their single-provider, well-charac-
terised public health care system.5
In a recent issue of Âlimentary Pharmacology and
Therapeutics, Nilsson et al. characterised the overall bur-
den of cirrhosis in southern Sweden from 2001 to 2011.6
Using the population-based medical registries in Sweden,
the authors identified 1317 patients with cirrhosis.
Patients were followed up for a median of 4.3 years and
the annual incidence of liver cirrhosis was estimated as
14.1/100 000. Alcoholic related liver disease was the
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overwhelming aetiology (58%) and ascites was the pri-
mary clinical manifestation at the time of diagnosis
(43%). The 1-, 5- and 10-year survival rates were found
to be 79%, 47% and 27% respectively. Furthermore, men
and patients with HCV with concomitant alcoholic liver
disease had the worst survival rates.6
This study has several strengths including a large sam-
ple size, length of longitudinal follow-up and robust data
available for review given the medical infrastructure in
Sweden. There are a few notable limitations and unad-
dressed questions that remain however. Inherent to any
retrospective study are the limitations in terms of
accurately identifying patients with cirrhosis, capturing
complications from cirrhosis, and relevant comorbidities.7
Assessing the presence of alcohol abuse is particularly dif-
ficult, and in this study is likely under-represented as it
was defined using only presence of these diagnoses in the
patient’s medical chart. The author’s approach to catego-
rization of aetiology of liver disease is also of interest,
specifically the reliability of the diagnosis of NASH and
the separation of NASH and cryptogenic cirrhosis. It
would have been of interest to also evaluate these two
groups combined given that prior studies have demon-
strated that significant proportions of patients defined as
having cryptogenic cirrhosis were likely due to NAFLD.8
Last, it would be of interest to outline the rank in the
order of aetiologies of cirrhosis on burden of death.
Overall this study adds to the existing body of litera-
ture on the global disease burden, natural history, and
associated morbidity and mortality related to end stage
liver disease. In particular, this study emphasises the
importance of addressing modifiable risk factors, specifi-
cally alcohol overuse as this aetiology portended a worse
prognosis in this cohort. In the wake of the impact of
direct-acting anti-virals for chronic hepatitis C, alcohol
related liver disease and non-alcoholic fatty liver disease
will account for progressively larger proportions of the
patient population with chronic liver disease and thus
represent target areas for research and clinical attention.9
Future studies are needed to identify means to improve
outcomes among these high risk patient populations.
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